We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Researchers at the Cancer Research UK-AstraZeneca Antibody Alliance Laboratory in Cambridge, UK, have developed a new technique able to generate an inhibitory, high-affinity antibody against Arginase 2 (ARG2), an enzyme implicated in major human diseases.